Opsona Therapeutics lands €3m in funding

Former Trinity College campus company Opsona Therapeutics has landed a further €3 million in funding, which will help finance planned tests on its lead product and boost its treatment potential.

The drug development firm yesterday announced the addition of Paris-based private equity firm Omnes Capital to its list of investors, who have pumped more than €30m into the firm this year.

Back in April, Opsona raised €33m with the likes of Sunstone Capital, Baxter Venture, BB Biotech Ventures and Amgen Ventures linking with its existing backers like Fountain Healthcare Partners and Novartis Venture Fund.